Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts

Clinical Cancer Research

Volumn 8, Issue 1, 2002, Pages 221-232

  Klement, Giannoula ^a   Huang, Ping ^a   Mayer, Barbara ^a   Green, Shane K ^a   Man, Shan ^a   Kerbel, Robert S ^a,c   Bohlen, Peter ^b   Hicklin, Daniel ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0036152447     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
2. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
3. 1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571
4. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
5. Cancer: Looking outside the genome
6. Modulation of multidrug resistance: A paradigm for translational clinical research
7. Redefining the target: Chemotherapeutics as antiangiogenics
8. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
9. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
10. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
11. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies
12. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
13. High-time chemotherapy or high time for low dose
14. Treatment of non-small-cell lung cancer with prolonged oral etoposide
15. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer
16. Oral cancer chemotherapy: The promise and the pitfalls
17. Endothelial cell survival and apoptosis in the tumor vasculature
18. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
19. Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells
20. The reversal of multidrug resistance in multicellular tumor spheroids by SDZ PSC 833
21. Cell and environment interactions in tumor microregions: The multicell spheroid model
22. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library
23. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy
24. Reversible inhibition of mammary gland growth by transforming growth factor-beta
25. The biochemistry of P-glycoprotein-mediated multidrug resistance
26. Restoration of Taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446
27. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC
28. Carboplatin differentially induces the VEGF stress response in endothelial cells: Potentiation of anti-tumor effects by combination with antibody to VEGF
29. Low dose of CDDP can modulate the sensitivity of human non-small cell lung carcinoma cells to EGFR kinase inhibitor (ZD1839; "Iressa") in vivo
30. Assessing tumors in living animals through measurement of urinary β-human chorionic gonadotropin
31. Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil
32. Modulation of doxorubicin sensitivity and level of P-glycoprotein expression in human colon carcinoma cells by ectopic and orthotopic environments in nude mice
33. Rearrangements of the cellular p53 gene in erythroleukemia cells transformed by Friend virus
34. Chemotherapy of mammary carcinomas arising in ras transgenic mice. Invest
35. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth
36. Weekly Taxol (T) in patients who had relapsed or remained stable with T in a 21 day schedule
37. Frequent, moderate-dose cyclophosphamide administration improves the efficiacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy
38. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide
39. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels
40. Continuous low-dose antiangiogenic (metronomic) chemotherapy: From the research laboratory into the oncology clinic